Muller-Hermelink; Hans-Konrad

Patent Applications and Registrations

Patent applications and USPTO patent grants for Muller-Hermelink; Hans-Konrad.The latest application filed is for "survival predictor for diffuse large b cell lymphoma".

Company Profile

1.9.16

Muller-Hermelink; Hans-Konrad - Wurzburg DE
Muller-Hermelink; Hans-Konrad - Wrzburg DE
Muller-Hermelink; Hans-Konrad - Wuerzburg DE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Survival predictor for diffuse large B cell lymphoma Grant 11,028,444 - Rimsza , et al. June 8, 2	2021-06-08
Methods for identifying, diagnosing, and predicting survival of lymphomas Grant 10,697,975 - Staudt , et al.	2020-06-30
Survival Predictor For Diffuse Large B Cell Lymphoma App 20180245165 - Rimsza; Lisa M. ; et al.	2018-08-30
Survival predictor for diffuse large B cell lymphoma Grant 9,970,059 - Rimsza , et al. May 15, 2	2018-05-15
Methods For Identifying, Diagnosing, And Predicting Survival Of Lymphomas App 20180011106 - Staudt; Louis M. ; et al.	2018-01-11
Survival Predictor For Diffuse Large B Cell Lymphoma App 20150132297 - Rimsza; Lisa ; et al.	2015-05-14
Adenocarcinoma specific antibody SAM-6, and uses thereof Grant 8,741,296 - Vollmers , et al. June 3, 2	2014-06-03
Adenocarcinoma Specific Antibody Sam-6, And Uses Thereof App 20130039849 - VOLLMERS; HEINZ ; et al.	2013-02-14
Methods For Identifying, Diagnosing, And Predicting Survival Of Lymphomas App 20120225793 - Staudt; Louis M. ; et al.	2012-09-06
Adenocarcinoma specific antibody SAM-6, and uses thereof Grant 8,163,552 - Vollmers , et al. April 24, 2	2012-04-24
Methods for identifying, diagnosing, and predicting survival of lymphomas Grant 8,131,475 - Staudt , et al. March 6, 2	2012-03-06
Survival Predictor For Diffuse Large B Cell Lymphoma App 20110195064 - Rimsza; Lisa ; et al.	2011-08-11
Anti-idiotype Antibodies Of The Human Monoclonal Antibody Sc-1, And Their Production And Use App 20100316630 - VOLLMERS; HEINZ PETER ; et al.	2010-12-16
Anti-idiotype antibodies of the human monoclonal antibody SC-1, and their production and use Grant 7,611,894 - Vollmers , et al. November 3, 2	2009-11-03
Neoplasm-specific polypeptides and their uses App 20090136420 - Muller-Hermelink; Hans Konrad ; et al.	2009-05-28
Neoplasm-specific polypeptides and their uses Grant 7,378,247 - Muller-Hermelink , et al. May 27, 2	2008-05-27
Adenocarcinoma Specific Antibody Sam-6, and Uses Thereof App 20080108133 - Vollmers; Heinz ; et al.	2008-05-08
Anti-Idiotype Antibodies of the Human Monoclonal Antibody Sc-1, and Their Production and Use App 20070269425 - Vollmers; Heinz Peter ; et al.	2007-11-22
Methods of Identifying Neoplasm-Specific Antibodies and Uses Thereof App 20070244304 - Vollmers; Heinz Peter ; et al.	2007-10-18
Methods for identifying, diagnosing, and predicting survival of lymphomas App 20070105136 - Staudt; Louis M. ; et al.	2007-05-10
Neoplasm-specific polypeptides and their uses App 20050032134 - Muller-Hermelink, Hans Konrad ; et al.	2005-02-10
Antibodies against plasma cells App 20030180799 - Muller- Hermelink, Hans Konrad ; et al.	2003-09-25

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.